Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine

Fujiwara, Naoto, Friedman, Scott L., Goossens, Nicolas, Hoshida, Yujin·2018·Journal of Hepatology
DOI 10.1016/j.jhep.2017.09.016

Cites (311)

Items 201–311 of 311

  1. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
    Peretinoin Study Group, Okita, Kiwamu, Izumi, Namiki, Matsui, Osamu, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi et al. · 2015 · Journal of Gastroenterology
  2. Dysregulated Krüppel-Like Factor 4 and Vitamin D Receptor Signaling Contribute to Progression of Hepatocellular Carcinoma
    Qi Li, Yong Gao, Zhiliang Jia, Lopa Mishra, Kun Guo, Zhiwei Li, Xiangdong Le, Daoyan Wei, Suyun Huang, Keping Xie · 2012 · Gastroenterology
  3. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study
    Hélène Vandenbulcke, Christophe Moreno, Isabelle O. Colle, Jean‐François Knebel, Sven Francque, Thomas Sersté, Christophe George, Chantal de Galocsy, Wim Laleman, Jean Delwaide et al. · 2016 · Journal of Hepatology
  4. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
    Ma, Shujuan, Zheng, Yixiang, Xiao, Yanni, Zhou, Pengcheng, Tan, Hongzhuan · 2017 · Medicine
  5. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma
    Yulin Sun, Guang-Zhou Gao, Jianqiang Cai et al. · 2012 · Carcinogenesis
  6. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model
    Kai Takegoshi, Masao Honda, Hikari Okada, Riuta Takabatake, Naoto Nagata, Jean S. Campbell, Masashi Nishikawa, Tetsuro Shimakami, Takayoshi Shirasaki, Yoshio Sakai et al. · 2017 · Oncotarget
  7. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease
    Katharine M. Irvine, Leesa F. Wockner, Mihir Shanker, Kevin J. Fagan, Leigh Ula Horsfall, Linda Maria Fletcher, Jacobus P J Ungerer, Carel Jacobus Pretorius, Gregory C. Miller, Andrew Donald Clouston et al. · 2015 · Liver International
  8. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B
    Kung‐Hao Liang, Chao‐Wei Hsu, Ming‐Ling Chang · 2015 · The Journal of Infectious Diseases
  9. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma
    Simonetta Bandiera, C. Billie Bian, Yujin Hoshida, Thomas F. Baumert, Mirjam B. Zeisel · 2016 · Current Opinion in Virology
  10. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor
    Andreas P. Sutter, Kerstin Maaser, Michael Höpfner, Alexander Huether, Detlef Schuppan, Hans Scherübl · 2005 · Journal of Hepatology
  11. Cost effectiveness of regorafenib as second‐line therapy for patients with advanced hepatocellular carcinoma
    Neehar D. Parikh, Amit G. Singal, David W. Hutton · 2017 · Cancer
  12. Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges
    Yujin Hoshida, Bryan C. Fuchs, Kenneth K. Tanabe · 2012 · Current Cancer Drug Targets
  13. Growth Rate of Hepatocellular Carcinoma
    Bachir A. Taouli, Jeffrey Seow Kuang Goh, Ying Lü · 2005 · Journal of Computer Assisted Tomography
  14. Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis
    Xiaobo Jia, Jiao Liu, Yingtang Gao, Yong Lin Huang, Du Zhi · 2014 · Archives of Medical Research
  15. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma
    Mengjun Wang, Karthik Devarajan, Amit G. Singal, Jorge A. Marrero, Jianliang Dai, Ziding Feng, Jo Ann Rinaudo, Sudhir Srivastava, Alison A. Evans, H W Hann et al. · 2015 · Cancer Prevention Research
  16. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2
    Xu, Yaping, Zhao, Wenxiu, Xu, Jianfeng, Li, Jie, Hong, Zaifa, Yin, Zhenyu, Wang, Xiaomin · 2016 · Oncotarget
  17. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios
    Ross Harris, Brenda Thomas, Jade Griffiths, Annastella Costella, Ruth Chapman, Mary Elizabeth Ramsay, Daniela De Angelis, Helen Harris · 2014 · Journal of Hepatology
  18. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis
    Danielle K. DePeralta, Lan Wei, Sarani Ghoshal, Benjamin H. Schmidt, Gregory Yves Lauwers, Michael D. Lanuti, Raymond T. Chung, Kenneth K. Tanabe, Bryan C. Fuchs · 2016 · Cancer
  19. lncRNA HULC promotes the growth of hepatocellular carcinoma cells via stabilizing COX-2 protein
    Haojun Xiong, Bo Li, Jintao He, Yijun Zeng, Yan Zhang, Fengtian He · 2017 · Biochemical and Biophysical Research Communications
  20. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
    Christophe Duvoux, Christian Toso · 2015 · Transplantation Reviews
  21. Neoplastic disease after liver transplantation: Focus onde novoneoplasms
    Patrizia Burra · 2015 · World Journal of Gastroenterology
  22. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
    Lindsay Y. King, Claudia Canasto‐Chibuque, Kara B. Johnson, Shun H. Yip, Xintong Chen, Kensuke Kojima, Manjeet Deshmukh, Anu Venkatesh, Poh Seng Tan, Xiaochen Sun et al. · 2014 · Gut
  23. Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome
    Yi Huang, W. Bastiaan de Boer, Leon Anton Adams · 2014 · Journal of Hepatology
  24. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy
    KC Chang, Y-Y Wu, Chien‐Hui Hung et al. · 2013 · British Journal of Cancer
  25. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients
    Antonio Facciorusso, Valentina Del Prete, Nicola Crucinio, Nicola Muscatiello, Brian Irving Carr, Alfredo Di Leo, M. Barone · 2015 · Journal of Gastroenterology and Hepatology
  26. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma
    Yaoyao Zhou, Gui‐Qi Zhu, Yue Wang · 2016 · Oncotarget
  27. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C ‐related liver disease and costs in A ustralia
    William Sievert, Homie A. Razavi, Chris R. Estes · 2014 · Journal of Gastroenterology and Hepatology
  28. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
    Won Sohn, Ju‐Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin‐Ho Jung, Yong‐Han Paik · 2017 · Clinical and Molecular Hepatology
  29. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999‐2010
    Qian Xiao, Rashmi R. Sinha, Barry I. Graubard, Neal D. Freedman · 2014 · Hepatology
  30. Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B
    Grace Lai‐Hung Wong, Henry Lik‐Yuen Chan, Hoi–Yun Chan, Chi‐Hang Tse, Angel Mei–Ling Chim, Angeline Oi–Shan Lo, Vincent Wai‐Sun Wong · 2014 · Clinical Gastroenterology and Hepatology
  31. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case‐control study
    Gyuri Kim, Suk‐Yong Jang, Eugene Han, Yong‐ho Lee, Se‐young Park, Chung Mo Nam, Eun Seok Kang · 2016 · International Journal of Cancer
  32. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data
    Monica A. Konerman, Yiwei Zhang, Ji Zhu, Peter Higgins, Anna Suk-Fong Lok, Akbar K. Waljee · 2015 · Hepatology
  33. Optimizing mouse models for precision cancer prevention
    Clémentine Le Magnen, Aditya Dutta, Cory T. Abate-Shen · 2016 · Nature reviews. Cancer
  34. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway
    Hsin-Hwa Tsai, Hong-Yue Lai, Yueh-Chiu Chen, Chien‐Feng Li, Huei‐Sheng Huang, Hsiao‐Sheng Liu, Yau-Sheng Tsai, Ju‐Ming Wang · 2017 · Oncotarget
  35. Hepatitis D and hepatocellular carcinoma
    Zaigham Abbas · 2015 · World Journal of Hepatology
  36. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies
    Catherine Fauvelle, Che C. Colpitts, Zhen–Yong Keck, Brian G. Pierce, Steven K. H. Foung, Thomas F. Baumert · 2016 · Expert Review of Vaccines
  37. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH
    Eduardo Vilar‐Gómez, Luis Calzadilla Bertot, Scott L. Friedman, Bienvenido Gra‐Oramas, Licet Gonzalez‐Fabian, Sacha Lazo del Vallín, Moisés Diago M, Leon Anton Adams · 2017 · Liver International
  38. Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC
    Mengjun Wang, Miloslav Šanda, Mary Ann Comunale, Harmin Herrera, Charles S. Swindell, Yuko Kono, Amit G. Singal, Jorge B Marrero, Timothy M. Block, Radoslav Goldman et al. · 2017 · Cancer Epidemiology Biomarkers & Prevention
  39. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase
    Ju Dong Yang, Jianliang Dai, Amit G. Singal, Purva Gopal, Benyam D. Addissie, Mindie H. Nguyen, Alex S. Befeler, K. Rajender Reddy, Myron Schwartz, Denise M. Harnois et al. · 2017 · Cancer Epidemiology Biomarkers & Prevention
  40. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine
    Cristina Stasi, Caterina Silvestri, Fabio Voller · 2015 · Journal of Infection and Public Health
  41. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case–control study
    Utaroh Motosugi, Tomoaki Ichikawa, Tsuyota Koshiishi · 2012 · European Radiology
  42. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
    Issei Saeki, Naoki Yamamoto, Takahiro Yamasaki, Taro Takami, Masaki Maeda, Koichi Fujisawa, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa et al. · 2016 · World Journal of Gastroenterology
  43. Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases
    Ke‐Qin Hu · 2003 · Prostaglandins Leukotrienes and Essential Fatty Acids
  44. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK
    Borna Relja · 2010 · International Journal of Oncology
  45. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
    Yosui Tamaki, Yukiomi Nakade, Taeko Yamauchi, Yuichi Makino, Shiro Yokohama, Mitsuyoshi Okada, Kazunobu Aso, Hiroyuki Kanamori, Tomohiko Ohashi, Ken Sato et al. · 2012 · Journal of Gastroenterology
  46. Acyclic Retinoid Targets Platelet-Derived Growth Factor Signaling in the Prevention of Hepatic Fibrosis and Hepatocellular Carcinoma Development
    Hikari Okada, Masao Honda, Jean S. Campbell et al. · 2012 · Cancer Research
  47. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma
    Takaaki Higashi, Hiromitsu Hayashi, Yuki Kitano, Kensuke Yamamura, Takayoshi Kaida, Kota Arima, Katsunobu Taki, Shigeki Nakagawa, Hirohisa Okabe, Hidetoshi Nitta et al. · 2016 · Medical Oncology
  48. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach
    Abbas Mourad, Sylvie Deuffic‐Burban, Nathalie Ganne‐Carrié, Thibaud Renaut-Vantroys, Isabelle Rosa, Anne‐Marie Bouvier, Guy D. Launoy, Stéphane Cattan, Alexandre Louvet, Sébastien Dharancy et al. · 2013 · Hepatology
  49. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening
    Yi-Chun Hung, Chih‐Lin Lin, Chun‐Jen Liu · 2014 · Hepatology
  50. Epidermal Growth Factor Gene Polymorphism and Risk of Hepatocellular Carcinoma: A Meta-Analysis
    Jian‐Hong Zhong, Xue‐Mei You, Wen‐Feng Gong, Liang Ma, Yu Zhang, Qinguo Mo, Liucheng Wu, Jun Feng Xiao, Le‐Qun Li · 2012 · PLoS ONE
  51. Trends in alcohol consumption in Europe and their impact on major alcohol-related cancers
    Carlo La Vecchia, Cristina Bosetti, Paola Bertuccio, Clara Castro, Claudio Pelucchi, Eva Negri · 2013 · European Journal of Cancer Prevention
  52. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
    Frank Erhard Uschner, Ganesh Ranabhat, Steve S. Choi, M Granzow, Sabine Klein, Robert Schierwagen, Esther Raskopf, Sebastian Gautsch, Peter F. M. van der Ven, Dieter O. Fürst et al. · 2015 · Scientific Reports
  53. Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice
    Daishi Terakura, Miho Shimizu, J. Iwasa, A. Baba, T. Kochi, Takatoshi Ohno, M. Kubota, Yohei Shirakami, Makoto Shiraki, K. Takai et al. · 2012 · Carcinogenesis
  54. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population
    Talita Duarte‐Salles, Sandeep Kumar Misra, Magdalena Stępień, Amelie Plymoth, David C. Muller, Kim Overvad, Anja Olsen, Anne Marie Tjønneland, Laura Baglietto, Gianluca Severi et al. · 2016 · Cancer Prevention Research
  55. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
    Benedetta Donati, Alessandro Pietrelli, Piero Pingitore, Paola Dongiovanni, Andrea Marco Caddeo, Lucy Walker, Guido Baselli, Serena Pelusi, Chiara Rosso, Ester Vanni et al. · 2017 · Cancer Medicine
  56. Dietary fat, fat subtypes and hepatocellular carcinoma in a large E uropean cohort
    Talita Duarte‐Salles, Veronika Fedirko, Magdalena Stępień et al. · 2015 · International Journal of Cancer
  57. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial
    Hitoshi Yoshiji · 2011 · Oncology Reports
  58. Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic
    Frank Louis Meyskens, Gregory A. Curt, Dean E. Brenner · 2011 · Cancer Prevention Research
  59. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.
    Xingkai Liu, Ping Zhang, Robert C.G. Martin, Guozhen Cui, Guangyi Wang, Yi Tan, Lu Cai, Guoyue Lv, Yan Li · 2016 · PubMed Central
  60. Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies
    Mei–Hsuan Lee, Sheng‐Nan Lu, Yong Yuan · 2014 · PLoS ONE
  61. Alcoholic Cirrhosis and Hepatocellular Carcinoma
    Felix Stickel · 2014 · Advances in experimental medicine and biology
  62. Branched-Chain Amino Acids Ameliorate Fibrosis and Suppress Tumor Growth in a Rat Model of Hepatocellular Carcinoma with Liver Cirrhosis
    Jung Hoon, Si Hyun Bae, Hye Lim Kim, Na Ri Park, Eun Suk Choi, Eun Sun Jung, Jong Young Choi, Seung Kew Yoon · 2013 · PLoS ONE
  63. Branched-Chain Amino Acids Enhance Premature Senescence through Mammalian Target of Rapamycin Complex I-Mediated Upregulation of p21 Protein
    Masayuki Nakano, Akio Nakashima, Taiki Nagano, Shintaro Ishikawa, Ushio Kikkawa, Shinji Kamada · 2013 · PLoS ONE
  64. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression
    Janine Kah, A Wüstenberg, Amelie Dorothea Keller, Hüseyin Sirma, Roberta Montalbano, Matthias Ocker, Tassilo Volz, Maura Dandri, Gisa Tiegs, Gabriele Sass · 2012 · Oncology Reports
  65. Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy
    Tong‐Hong Wang, Tse‐Ching Chen, Xiao Teng · 2015 · Scientific Reports
  66. The use of Sirolimus should be restricted in liver transplantation
    Omar I. Massoud, Russell H. Wiesner · 2011 · Journal of Hepatology
  67. Liver stiffness‐based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis
    Seung Hwan Shin, Seung Up Kim, Jun Yong Park · 2014 · Liver International
  68. Treatment of alcoholic liver disease
    Christopher Paul Day · 2007 · Liver Transplantation
  69. A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis
    Xavier Verhelst, Dieter Vanderschaeghe, Laurent Castéra, Tom Raes, Anja M. Geerts, Claire Francoz, Roos Colman, François Durand, Nico Callewaert, Hans Van Vlierberghe · 2016 · Clinical Cancer Research
  70. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.
    1998 · PubMed
  71. A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis
    Pierre Nahon, Angéla Sutton, Pierre Rufat, Nathalie Charnaux, Abdellah Mansouri, Richard Moreau, Nathalie Ganne‐Carrié, Véronique Grando–Lemaire, G. Nkontchou, Jean–Claude Trinchet et al. · 2011 · Journal of Hepatology
  72. Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering
    Bernard Y.K. Binder, Priscilla A. Williams, Eduardo Alexandre Silva, Jonathan Kent Leach · 2015 · Tissue Engineering Part B Reviews
  73. Liver stiffness‐based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy
    Jing‐Houng Wang, Yi‐Hao Yen, Chih‐Chien Yao · 2016 · Liver International
  74. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)
    Reem Waziry, Jason Grebely, Janaki Amin · 2016 · Journal of Hepatology
  75. Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload
    Morgan Preziosi, Sucha Singh, Erika V. Valore, Grace Jung, Branimir Popovic, Minakshi Poddar, Shanmugam Nagarajan, Tomas Ganz, Satdarshan P. Monga · 2017 · Journal of Hepatology
  76. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon
    Bart J. Veldt, Bettina E. Hansen, Kenji Ikeda, Elke Verhey, Hiroshi Suzuki, Solko Walle Schalm · 2006 · Scandinavian Journal of Gastroenterology
  77. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway
    Charlotte E. Edling, Federico Selvaggi, Ragheda Ghonaim, Tania Maffucci, Marco Falasca · 2014 · Cancer Biology & Therapy
  78. Nucleot(s)ide Analogues for Hepatitis B Virus-Related Hepatocellular Carcinoma after Curative Treatment: A Systematic Review and Meta-Analysis
    Ping Sun, Xiaochuan Dong, Xiang Chao Cheng · 2014 · PLoS ONE
  79. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
    The Peretinoin Study Group, Kiwamu Okita, Namiki Izumi et al. · 2014 · Journal of Gastroenterology
  80. Hepatocellular Carcinoma Presenting at Contrast-Enhanced Multi–Detector-Row Computed Tomography or Gadolinium-Enhanced Magnetic Resonance Imaging as a Small (≤2 cm), Indeterminate Nodule
    Alessandro Furlan, Daniele Marin, Francesco Agnello · 2012 · Journal of Computer Assisted Tomography
  81. Prediction of Fibrosis Progression Rate in Patients with Chronic Hepatitis C Genotype 4: Role of Cirrhosis Risk Score and Host Factors
    Tarek A. Besheer, Mahmoud El‐Bendary, Hatem Elalfy, Mohamed Abd El-Maksoud, Mohamed Salah, Khaled Refaat Zalata, Wagdi Fawzi Elkashef, Heba A. Elshahawy, Doaa M. Raafat, Wafaa Elemshaty et al. · 2017 · Journal of Interferon & Cytokine Research
  82. Anti-inflammatory Effect of Pitavastatin on NF-.KAPPA.B Activated by TNF-.ALPHA. in Hepatocellular Carcinoma Cells
    Juyong Wang, Takashi Tokoro, Susumu Higa, Isao Kitajima · 2006 · Biological and Pharmaceutical Bulletin
  83. Alcohol and liver cancer
    Carlo La Vecchia · 2007 · European Journal of Cancer Prevention
  84. Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases
    Tomoko Aoki, Hiroko Iijima, Toshifumi Tada, Takashi Kumada, Takashi Nishimura, Chikage Nakano, Kyohei Kishino, Yoshihiro Shimono, Kazunori Yoh, Ryo Takata et al. · 2016 · Journal of Gastroenterology
  85. Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature
    Atsushi Ono, Nicolas Goossens, Richard S. Finn · 2017 · Hepatology
  86. The Epidemiological Investigation on the Risk Factors of Hepatocellular Carcinoma
    Jianjun Niu, Yong Lin, Zhinan Guo, Mu Niu, Chenghao Su · 2016 · Medicine
  87. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer
    Derek J. Erstad, Andrew Martin Tager, Yujin Hoshida · 2017 · Molecular & Cellular Oncology
  88. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet
    Hikari Okada, Riuta Takabatake, Masao Honda, Kai Takegoshi, Taro Yamashita, Mikiko Nakamura, Takayoshi Shirasaki, Yoshio Sakai, Tetsuro Shimakami, Naoto Nagata et al. · 2017 · Oncotarget
  89. HCV elimination — lessons learned from a small Eurasian country, Georgia
    Muazzam Nasrullah, David Sergeenko, Amiran Gamkrelidze · 2017 · Nature Reviews Gastroenterology & Hepatology
  90. Branched‐chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein‐expressing mice
    Masaaki Korenaga, Sohji Nishina, Keiko Korenaga, Yasuyuki Tomiyama, Naoko Yoshioka, Yuichi Hara, Yusuke Sasaki, Yasushi Shimonaka, Keisuke Hino · 2014 · Liver International
  91. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
    Yuko Takami, Susumu Eguchi, Masaki Tateishi · 2016 · Hepatology International
  92. Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis.
    Huiling Sun, Qiwen Deng, Yuqin Pan · 2015 · PubMed
  93. Cost Effectiveness of Pre– vs Post–Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals
    Sumeyye Samur, Brian Kues, Turgay Ayer · 2017 · Clinical Gastroenterology and Hepatology
  94. Interferon‐alpha‐induced hepatitis C virus clearance restores p53 tumor suppressor more than direct‐acting antivirals
    Yücel Aydın, Animesh Chatterjee, Partha Kumar Chandra, Srinivas Prabhu Chava, Weina Chen, Anamika Tandon, Asha Dash, Milad Chedid, Martin Moehlen, Frederic Regenstein et al. · 2017 · Hepatology Communications
  95. Atorvastatin Decreases HBx-Induced Phospho-Akt in Hepatocytes via P2X Receptors
    Aram Ghalali, Javier Martín‐Renedo, Johan Högberg, Ulla Stenius · 2017 · Molecular Cancer Research
  96. Rosuvastatin limits the activation of hepatic stellate cells in diet‐induced obese mice
    Thatiany de Souza Marinho, Adriana Kawasaki, Marcus Bryntesson, Vanessa Souza‐Mello, Sandra Barbosa‐da‐Silva, Márcia Barbosa Águila, Carlos Alberto Mandarim‐de‐Lacerda · 2016 · Hepatology Research
  97. The Acyclic Retinoid Peretinoin Inhibits Hepatitis C Virus Replication and Infectious Virus Release in Vitro
    Tetsuro Shimakami, Masao Honda, Takayoshi Shirasaki et al. · 2014 · Scientific Reports
  98. Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?
    Nicolas Goossens, C. Billie Bian, Yujin Hoshida · 2017 · Current Hepatology Reports
  99. Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity
    Tarik Asselah, Ponni Perumalswami, Douglas T. Dieterich · 2014 · Liver International
  100. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP
    Timothy R.M. Morgan, Kathryn Osann, Teodoro Bottiglieri et al. · 2015 · Cancer Prevention Research
  101. Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C
    Sabela Lens, Ferràn Torres, Marc Puigvehí et al. · 2015 · Alimentary Pharmacology & Therapeutics
  102. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma
    Ki Tae Suk, Eun Jin Kim, Dong Joon Kim, Hyo Sun Kim, Chang Seok Bang, Tae Young Park, Gwang Ho Baik, Sung Eun Kim, Ji Won Park, Sang Hoon Park et al. · 2016 · Journal of Clinical Gastroenterology
  103. Oral Cancer Chemoprevention—The End of EPOC, the Beginning of an Epoch of Molecular Selection
    Julie E. Bauman, Jennifer Rubin Grandis · 2015 · JAMA Oncology
  104. Prospective evidence of a circulating microRNA signature as a non-invasive marker of hepatocellular carcinoma in HBV patients
    Chun Wang, HIE-WON L. HANN, Zhong Ye et al. · 2016 · Oncotarget
  105. Synergistic effect of simvastatin plus NS 398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line
    Sun-Jae Lee, Ji Won Hwang, Hyungshin Yim et al. · 2013 · Journal of Gastroenterology and Hepatology
  106. Acyclic retinoid induces differentiation and apoptosis of murine hepatic stem cells
    Hong-Bin Guan, Yunzhong Nie, Yun‐Wen Zheng, Kazuya Takiguchi, Hongwei Yu, Ranran Zhang, Bin Li, T. Tsuchida, Hideki Taniguchi · 2015 · Stem Cell Research & Therapy
  107. Reducing Liver Cancer Risk in African-Born Immigrants Through Culturally Targeted Hepatitis B Group Education Programs
    Kemi Bolutayo, Alexandre Ly van manh, Noah A. Cohen · 2017 · Journal of Cancer Education
  108. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection – first announcement of the protocol
    Shuang-Jian Qiu, Zhongguo Zhou, Feng Shen · 2015 · Expert Opinion on Biological Therapy
  109. Genetic Polymorphism of Epidermal Growth Factor rs4444903 Influences Susceptibility to HCV-Related Liver Cirrhosis and Hepatocellular Carcinoma in a Chinese Han Population:
    Shitian Zhang, Kunyan Qiao, Congdoanh Trieu · 2017 · Clinical Laboratory
  110. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C
    Chung‐Feng Huang, Ching‐I Huang, Ming‐Lun Yeh et al. · 2017 · Oncotarget
  111. Peretinoin as an adjuvant therapy for hepatocellular carcinoma
    Chee‐Kiat Tan · 2016 · Expert Review of Gastroenterology & Hepatology